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Aims To investigate the ability of SYNTAX score and Clinical SYNTAX score (CSS) to predict very long-term outcomes in
an all-comers population receiving drug-eluting stents.
Methods
and results
The SYNTAX score was retrospectively calculated in 848 patients enrolled in the SIRolimus-eluting stent compared
with pacliTAXel-Eluting Stent for coronary revascularization (SIRTAX) trial. The CSS was calculated using age, and
baseline left ventricular ejection fraction and creatinine clearance. A stratified post hoc comparison was performed
for all-cause mortality, cardiac death, myocardial infarction (MI), ischaemia-driven target lesion revascularization
(TLR), definite stent thrombosis, and major adverse cardiac events (MACE) at 1- and 5-year follow-up. Tertiles for
SYNTAX score and CSS were defined as SSLOW ≤7, 7, SSMID ≤14, SSHIGH .14 and CSSLOW ≤8.0, 8.0
,CSSMID ≤17.0 and CSSHIGH .17.0, respectively. Major adverse cardiac events rates were significantly higher in
SSHIGH compared with SSLOW at 1- and 5-year follow-up, which was also seen at 5 years for all-cause mortality,
cardiac death, MI, and TLR. Stratifying outcomes across CSS tertiles confirmed and augmented these results. Within
CSSHIGH, 5-year MACE increased with use of paclitaxel- compared with sirolimus-eluting stents (34.7 vs. 21.3%,
P ¼ 0.008). SYNTAX score and CSS were independent predictors of 5-year MACE; CSS was an independent predictor
for 5-year mortality. Areas-under-the-curve for SYNTAX score and CSS for 5-year MACE were 0.61 (0.56–0.65) and
0.62 (0.57–0.67), for 5-year all-cause mortality 0.58 (0.51–0.65) and 0.66 (0.59–0.73) and for 5-year cardiac death 0.63
(0.54–0.72) and 0.72 (0.63–0.81), respectively.
Conclusion SYNTAX score and to a greater extent CSS were able to stratify risk for very long-term adverse clinical outcomes in an all-
comers population receiving drug-eluting stents. Predictive accuracy for 5-year all-cause mortality was improved using CSS.
Trial Registration Number: NCT00297661.
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Introduction
The SYNTAX score is a lesion-based angiographic scoring system
originally devised to grade the complexity of coronary artery
disease1 and thereby facilitate consensus in the study of a diagnos-
tic angiogram between surgeons and interventional cardiologists. In
the SYNTAX trial,2 it proved effective in predicting clinical out-
comes after elective percutaneous coronary intervention (PCI)
procedures in patients with three-vessel and/or left main coronary
artery disease.3 The score’s predictive ability for a number of clini-
cal outcomes has subsequently been assessed in patient cohorts
with a varying extent of coronary artery disease undergoing both
elective and emergent PCI procedures.4– 13 Several of these
studies have suggested that, being solely based on angiographic
variables, the SYNTAX score cannot account for the variability
related to clinical factors which are widely acknowledged to
impact on long-term outcomes, such as a patients’ age,14 left ven-
tricular ejection fraction,15 and renal function.16
A clinical score incorporating the aforementioned variables, the
ACEF score, has been retrospectively validated in patients under-
going elective coronary artery bypass grafting (CABG)
operations.17 Integration of this score, modified through the repla-
cement of serum creatinine with creatinine clearance, with the
SYNTAX score, in the Clinical SYNTAX score (CSS), has been
shown to improve the predictive ability for adverse clinical out-
comes after PCI.10,11,18 However, information regarding the very
long-term performance of either SYNTAX score or CSS in an all-
comers population is currently lacking.
The SIRolimus-eluting stent compared with pacliTAXel-Eluting
Stent for coronary revascularization (SIRTAX) trial19 was a pro-
spective, observer-blind, randomized controlled study comparing
the safety and efficacy of sirolimus-eluting stents (SES) and
paclitaxel-eluting stents (PES) in 1012 patients undergoing PCI
for either stable angina or an acute coronary syndrome. This
study design offers a convenient setting for describing the distri-
bution of the SYNTAX score and CSS in an all-comers population.
Furthermore, the availability of 5-year follow-up data permits a
more robust evaluation of both scores, in order to confirm their
potential to risk stratify clinical outcomes at very long-term after
the implantation of drug-eluting stents.
Methods
Patient population and coronary intervention
The design of the SIRTAX trial has been previously described.19
Patients were eligible to participate if they presented at least one
lesion with percentage diameter stenosis ≥50%, in a vessel with a
reference diameter between 2.25 and 4.00 mm that was suitable for
stent implantation. There were no limitations on the number of
lesions treated, number of vessels diseased or on the length of the
lesions. The study complied with the Declaration of Helsinki regarding
investigation in humans and was approved by the institutional ethics
committees at the participating centres. Written informed consent
was obtained from each patient before enrollment. There was no
industry involvement in the design, conduct or analysis of the study.
Patients were randomly assigned on a 1:1 basis to treatment with SES
(Cypherw; Cordis, Warren, NJ, USA) or PES (Taxusw, Boston Scientific,
Natick, MA, USA). No mixture of drug-eluting stents was allowed within
a given patient. All procedures were performed according to interven-
tional standards at the time. Before or at the time of the procedure,
patients received at least 100 mg of aspirin, a 300 mg loading dose of clo-
pidogrel, and unfractionated heparin (70–100 U/kg of body weight).
After the procedure, all patients were advised to maintain aspirin life-
long, and clopidogrel therapy was prescribed for 12 months irrespective
of stent type.
SIRTAX endpoints and definitions
All adverse events were adjudicated by an independent clinical events
committee throughout 5 years and have been reported separately.20
The pre-specified primary endpoint was a composite of major
adverse cardiac events (MACE) including death from cardiac causes,
myocardial infarction (MI), and ischaemia-driven target lesion revascu-
larization (TLR). The diagnosis of MI was based on the presence of new
Q waves of at least 0.4 s duration in ≥2 contiguous leads and an elev-
ated creatine kinase MB fraction. In the absence of pathologic Q waves,
the diagnosis of MI was based on an increase in the creatine kinase
level to more than twice the upper limit of the normal range with
an elevated level of creatine kinase MB or troponin I. Target lesion
revascularization was defined as an intervention (either surgical or per-
cutaneous) to treat a stenosis within the stent or within the 5-mm
borders adjacent to the stent. Revascularization was considered to
be driven by ischaemia, if percentage diameter stenosis was ≥50%
on the basis of quantitative coronary angiography in the presence of
ischaemic signs or symptoms, or ≥70% even in the absence of ischae-
mic signs or symptoms.
Stent thrombosis was diagnosed as an acute coronary syndrome
with angiographic documentation of either target vessel occlusion or
thrombus within or adjacent to the previously stented segment; apply-
ing Academic Research Consortium recommendations,21 definite stent
thrombosis was documented.
SYNTAX score and angiographic analysis
The SYNTAX score algorithm, which is described in full elsewhere and
is available on the SYNTAX score website (www.syntaxscore.com),
was employed to retrospectively score all coronary lesions deemed
to have a percentage diameter stenosis ≥50%, in vessels ≥1.5 mm.
All angiographic variables pertinent to SYNTAX score calculation
were computed by two experienced interventional cardiologists
(C.G., S.G.) on diagnostic angiograms obtained before the procedure.
In case of disagreement, the opinion of a third analyst (G.S.) was
obtained and the final decision was made by consensus. Analysts
were blinded to procedural data and clinical outcome. The final
score was calculated on a patient basis from the individual lesion
scores, which were saved in a dedicated database, and was not made
available to the analysts until after the completion of the study.
Patients with acute MIs were not included in the SYNTAX trial. In
the context of our study the culprit lesions were scored using the
angiographic views of the infarct-related arteries before any interven-
tion; in the absence of flow these were scored as total occlusions of
,3-months’ duration.9 Patients with prior CABG operation were
excluded from the analysis; a dedicated amendment for calculating
the score in the presence of grafts has not been made available yet.
Finally, in-stent restenosis lesions were scored as de novo ones.
Clinical SYNTAX score
The modified ACEF score was retrospectively calculated,18 based on
the patients’ left ventricular ejection fraction, age, and creatinine clear-
ance derived using the Cockcroft–Gault equation.22 Respective
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methodology has been amply described elsewhere. Values for variables
included in the modified ACEF score were recorded before the index
PCI. Clinical SYNTAX score was calculated multiplying the value of
SYNTAX score by the modified ACEF score.
Statistics
Statistical analysis was performed using SPSS 17.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Patient characteristics and outcome measures
were stratified according to score tertiles among all patients with a cal-
culated CSS. Continuous variables are presented as mean+ 1 stan-
dard deviation (SD) or median values (25th to 75th percentile) as
appropriate; categorical variables are displayed as counts and/or per-
centages. Comparisons were performed with one-way analysis of var-
iance (ANOVA) for continuous variables following a normal
distribution and with the x2 test for categorical variables. The normal-
ity assumption was evaluated by the Kolmogorov–Smirnov test. Spear-
man’s rank correlation coefficient was used to measure the strength of
the association of SYNTAX score with CSS.
Cumulative event rates through all 5-years of follow-up were esti-
mated by means of the Kaplan–Meier method. Testing for trends in
event rates across score tertiles was done with the Cochran–Armitage
test in SAS software (SAS, version 9.2, Cary, NC, USA). All-cause mor-
tality, MACE, cardiac death, TLR, MI, and definite stent thrombosis
rates were compared across SYNTAX score and CSS tertiles accord-
ing to the Cox proportional-hazards model; the assumption of pro-
portional hazards was verified by visual inspection of the
log-minus-log curves. Independent predictors of 5-year MACE, all-
cause mortality, and cardiac death were sought among variables
significant beyond the level of P ¼ 0.10 in univariable analysis. Potential
predictors were checked for collinearity before entering a multivari-
able backward stepwise model; variables with a variance inflation
factor .2.5 were disqualified. Crude and adjusted hazard ratios and
corresponding 95% confidence intervals are reported for qualifying
variables.
SYNTAX score, CSS, and multivariable models were also evaluated
in terms of calibration and discrimination for 5-year MACE, cardiac,
and all-cause mortality. Calibration was evaluated with the Hosmer–
Lemeshow (H–L) goodness-of-fit test, wherein a lower x2 statistic
and a higher corresponding P-value implied a better match between
the estimated probabilities and the actual events. Discrimination was
explored with the areas under the receiver-operating characteristics
(ROC) curves; an area of 1.0 would indicate perfect discrimination,
whereas an area of 0.5 indicates the total absence of discriminatory
power. Areas-under-the-curves (AUCs) for SYNTAX score, CSS, and
multivariable models were compared with the DeLong method23
using MedCalc for Windows, version 11.6.0.0 (MedCalc Software,
Mariakerke, Belgium). Finally, in order to formally assess, whether
CSS improved the risk stratification over the SYNTAX score, a net
reclassification improvement (NRI) analysis was performed.24
To complete our analysis, a stratified comparison of clinical out-
comes between SES and PES was also performed across SYNTAX
score and CSS tertiles using Cox regression analysis. To determine
whether there was an interaction between treatment arm and
scores’ tertiles, likelihood ratio tests were used.
All statistical tests were two-sided and a P-value , 0.05 was
considered statistically significant.
Results
Analysis was performed for 848 patients (1792 lesions). Scores
were not evaluable in 91 cases due to prior CABG; another 57
angiograms were either not available or not fully evaluable in the
acquired views. Finally in 16 cases, data on creatinine clearance
could not be retrieved, consequently CSS could not be calculated;
clinical outcomes of these 164 patients excluded from the analysis
are shown in Supplementary material online, Table S1.
The SYNTAX score ranged from 1 to 42, with a mean+ SD of
11.7+ 7.3, and a median of 10 (6.0–16.0). The CSS ranged from
0.7 to 272.2, with a mean + SD of 17.4+ 20.5, and a median of
11.6 (6.4–21.2); expectedly, there was a strong correlation
between the two scores (r ¼ 0.87, P, 0.001). Both scores were
non-parametric and their distribution was skewed to the right
(Figure 1). Tertiles for SYNTAX score and CSS were defined as
SSLOW ≤7, 7, SSMID ≤14, SSHIGH .14 and CSSLOW ≤8.0,
8.0, CSSMID ≤17.0 and CSSHIGH .17.0, respectively.
Figure 1 Scores’ distribution in the SIRTAX trial population. Histograms of SYNTAX score (left side) and Clinical SYNTAX score (right side)
with superimposed normal curves; in both cases the distribution is skewed to the right. Histogram for Clinical SYNTAX score is truncated at
the 98th percentile value. Mean+ SD values and median values plus inter-quartile range (IQR) are reported.
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Baseline characteristics and risk factors stratified across
SYNTAX score tertiles are reported in Table 1 and data pertinent
to the procedure and the score calculation are reported in Table 2.
Stratified clinical outcomes
One-year outcomes across SYNTAX score tertiles are reported in
Supplementary material online, Table S2; 5-year outcomes across
SYNTAX score tertiles are shown in Figure 2. Five-year MACE
rates were significantly higher in SSHIGH compared with SSLOW
[24.2 vs. 12.5%, HR: 2.10 (1.40–3.16), P, 0.01], which was also
the case for 5-year all-cause mortality, cardiac death, MI,
and TLR rates; for all these endpoints there was a significant
trend (P ≤ 0.03) for higher event rates with increasing SYNTAX
score tertiles.
Stratifying outcomes across CSS tertiles (Table 3 and see Sup-
plementary material online, Table S3) led to similar results for
the comparisons between high and low score tertiles. However,
in contrast to the SYNTAX score analysis, event rates for MACE
and TLR were significantly higher in CSSHIGH compared with
both CSSMID and CSSLOW at 1- and 5-year follow-up; this held
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Table 1 Baseline clinical characteristics and risk factors
Characteristic SS ≤7 (n 5 293) 7< SS ≤14 (n 5 287) SS >14 (n 5 268) P-value
Age (years + SD) 60.7 + 10.6 61.4 + 11.2 63.7 + 11.3 0.004
Male gender, n (%) 218 (74.4) 219 (76.3) 211 (78.7) 0.48
Body mass index +SD 27.4 + 4.2 27.4 + 4.0 27.0 + 3.8 0.41
Diabetes mellitus, n (%) 45 (15.4) 50 (17.4) 66 (24.6) 0.04
Hypertension, n (%) 171 (58.4) 175 (61.0) 160 (59.7) 0.85
Hyperlipidaemia, n (%) 176 (60.1) 159 (55.4) 146 (54.5) 0.66
Current smoking, n (%) 124 (42.3) 100 (34.8) 93 (34.7) 0.41
Previous MI, n (%) 73 (24.9) 78 (27.2) 73 (27.2) 0.56
Previous PCI, n (%) 51 (17.4) 51 (17.8) 48 (17.9) 0.94
Peripheral vascular disease, n (%) 19 (6.5) 17 (5.9) 13 (4.9) 0.84
Stable angina pectoris, n (%) 163 (55.6) 115 (40.1) 108 (40.3) ,0.001
Acute coronary syndromes, n (%) 130 (44.4) 172 (59.9) 160 (59.7) ,0.001
Unstable angina, n (%) 14 (4.8) 23 (8.0) 12 (4.5)
Non ST-segment elevation MI, n (%) 74 (25.3) 61 (21.3) 63 (23.5)
ST-segment elevation MI, n (%) 42 (14.3) 88 (30.7) 85 (31.7)
Multi-vessel coronary artery disease, n (%) 96 (32.8) 107 (58.2) 209 (78.0) ,0.001
Left ventricular ejection fraction (% +SD) 60.2 + 9.4 56.8 + 11.4 53.3 + 12.6 ,0.001
Serum creatinine (mg/dL +SD) 0.93 + 0.33 0.95 + 0.54 1.02 + 0.83 0.14
Creatinine clearance (mL/min/1.73 m2 +SD) 98.6 + 34.9 99.5 + 35.8 91.6 + 34.8 0.02
MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; SS, SYNTAX score.
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Table 2 Procedural characteristics and lesions adjudicated in SYNTAX score
Characteristics per patient SS ≤7 (n5 293) 7 <SS ≤14 (n5 287) SS >14 (n 5 268) P-value
Mean number of lesions +SD 1.4 + 0.6 2.1 + 0.9 2.9 + 1.2 ,0.001
Bifurcation-trifurcation lesions +SD 0.1 + 0.3 0.6 + 0.6 0.9 + 0.8 ,0.001
Total occlusions +SD 0.1 + 0.3 0.3 + 0.5 0.6 + 0.6 ,0.001
Lesions treated +SD 1.2 + 0.5 1.4 + 0.6 1.5 + 0.6 ,0.001
One lesion treated, n (%) 237 (80.9) 180 (62.7) 150 (56.0) ,0.001
Two lesions treated, n (%) 49 (16.7) 91 (31.7) 99 (36.9)
Three lesions treated, n (%) 7 (2.4) 16 (5.6) 19 (7.1)
Mean number of stents +SD 1.1 + 0.3 1.2 + 0.4 1.2 + 0.6 ,0.001
Total stent length +SD 20.5 + 11.4 26.9 + 14.8 30.0 + 16.8 ,0.001
SES usage, n (%) 139 (47.4) 150 (52.3) 137 (51.1) 0.48
PES usage, n (%) 154 (52.6) 137 (47.7) 131 (48.9) 0.48
PES, paclitaxel-eluting stents; SD, standard deviation; SES, sirolimus-eluting stents; SS, SYNTAX score.
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Figure 2 Clinical outcomes at 5-year follow-up stratified across SYNTAX score tertiles. Kaplan–Meier curves are presented for major
adverse cardiac events, ischaemia-driven target lesion revascularization, myocardial infarction, all-cause mortality (death), cardiac death and defi-
nite stent thrombosis. Tertiles for SYNTAX score were defined as SSLOW ≤7, 7 ,SSMID ≤14, SSHIGH .14. Pairwise comparison results are
presented as hazard ratios plus 95% confidence intervals and respective P-values.
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also for all-cause mortality, cardiac death, and MI at 5 years. Defi-
nite stent thrombosis rates were directionally but not significantly
higher in CSSHIGH compared with both CSSMID and CSSLOW at
1-and 5-year follow-up.
SYNTAX Score vs. Clinical
SYNTAX score
The ROC curves for MACE, all-cause mortality, and cardiac death
at 5-year follow-up are shown in Figure 3. The AUC for CSS was
significantly larger compared with the one for SYNTAX
score regarding cardiac death [0.72 (0.63–0.81) vs. 0.63 (0.54–
0.72), P ¼ 0.002] and all-cause mortality [0.66 (0.59–0.73) vs.
0.58 (0.51–0.65), P, 0.001]. The AUC for MACE was decreased
for both scores, being not significantly larger for CSS [0.62 (0.57–
0.67) vs. 0.61 (0.56–0.65), P ¼ 0.24].
In terms of calibration, CSS was more robust compared with
SYNTAX score for all-cause mortality (x2 ¼ 6.148, P ¼ 0.63 vs.
x2 ¼ 7.674, P ¼ 0.36) and slightly less robust for cardiac death
(x2 ¼ 9.695, P ¼ 0.29 vs. x2 ¼ 7.377, P ¼ 0.39). Similar to discrimi-
nation, calibration for MACE was worse for SYNTAX score and
CSS when compared with that for mortality (x2 ¼ 9.968, P ¼
0.19 and x2 ¼ 15.619, P ¼ 0.05).
When reclassifying patients with all-cause mortality from SS into
CSS tertiles, 14/72 (19.5%) patients with events were moved to
higher risk categories (upward) and 3/72 (4.2%) to lower risk cat-
egories (downward), thus resulting in a net gain of 15.3% (Table 4).
In patients without events, 95 were moved downward and 99
upward, on aggregate a net loss of 0.5%; consequently the NRI
was 14.7% (z ¼ 2.46, P ¼ 0.014). Following the same
procedure, NRI for cardiac mortality was more pronounced
19.1% (z ¼ 2.36, P ¼ 0.018); on the other hand, NRI for patients
with MACE was negligible (0.6%, P ¼ 0.88) (see Supplementary
material online, Tables S4 and S5).
Multivariable analysis
Independent predictors for MACE, all-cause mortality and cardiac
death at 5-year follow-up are reported in Tables 5 and 6. Because
of the strong correlation between SYNTAX score and CSS, each
score was entered separately in the multivariable analysis together
with other variables significant in univariable analysis. There were
no collinearity issues among potential predictors, even when CSS
was tested together with left ventricular ejection fraction, age,
and creatinine clearance (variance inflation factor ,1.76 for all
parameters). Nevertheless, the latter three variables being com-
ponents of ACEF and hence of CSS, were left out of models includ-
ing CSS, in order to minimize collinearity.
Both scores were independent predictors of MACE (in separate
models) next to the number of treated lesions. Addition of dia-
betes did not significantly impact discrimination for either the
CSS (P ¼ 0.68) or the SYNTAX score model (P ¼ 0.88); cali-
bration improved for the former but got worse for the latter.
Regarding all-cause mortality, CSS was an independent predictor
next to diabetes. Addition of diabetes to CSS resulted in a
model with larger AUC (P ¼ 0.36) but worse calibration compared
with stand-alone CSS. Similar to all-cause mortality, CSS was an
independent predictor for cardiac death next to diabetes. Addition
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of diabetes to CSS resulted in a model with slightly larger AUC
(P ¼ 0.52) and better calibration compared with stand-alone CSS.
Stratified analysis of drug-eluting stents
performance
Overall adverse clinical event rates for each treatment arm are
reported in Table 7 for the 848 patients included in this substudy.
Stratified comparisons of PES vs. SES across CSS tertiles for clinical
outcome measures at 1- and 5-year follow-up are shown in
Figures 4 and 5, respectively. Among patients in the higher CSS
tertile, there was an increase in MACE rates with PES compared
with SES at 1-year follow-up [23.9 vs. 8.6%, HR: 3.02 (1.56–
5.83), P ¼ 0.001], which was mainly driven by increased
TLR rates in the PES arm [18.1 vs. 6.5%, HR: 2.91 (1.36–6.25),
P ¼ 0.004]. Higher MACE rates for the PES arm persisted at 5
years [34.7 vs. 21.3% for SES, HR: 1.85 (1.17–2.93), P ¼ 0.008],
whereas differences in TLR rates were no longer significant [22.0
vs. 14.0%, HR: 1.70 (0.96–3.02), P ¼ 0.07]. The interaction term
between treatment arm and CSS tertiles for 5-year MACE had a
P ¼ 0.050, suggesting a genuine effect, whereas for 1-year MACE,
P ¼ 0.10. Interaction term P-values for all-cause mortality, MI and
TLR were 0.76, 0.26, 0.29 at 1-year and 0.43, 0.18, 0.39 at 5-year
follow-up, respectively.
Stratifying outcome across SYNTAX score tertiles led to similar
results regarding the performance of PES vs. SES (see Supplemen-
tary material online, Figures S1 and S2). However, the interaction
term between treatment arm and SYNTAX score tertiles for all
endpoints at 1- and 5-year follow-up had a P-value consistently
.0.05; thus conclusions drawn from these results should be inter-
preted with caution.
Discussion
The main findings of this study indicate that the SYNTAX score,
and to a greater extent the CSS, have an important role to play
in the risk stratification of very long-term clinical outcomes in an
all-comers population receiving drug-eluting stents. Both scores
were identified as independent predictors of 5-year MACE, never-
theless having modest discriminatory power and calibration for this
endpoint. Clinical SYNTAX score was also an independent predic-
tor of 5-year all-cause mortality and cardiac death; its superior dis-
criminatory power and calibration compared with SYNTAX score
resulted in a significant improvement in risk stratification. An
additional potential role of the CSS in the assessment of stent per-
formance was also identified.
Although the current study employed comparable inclusion cri-
teria to the two most recent all-comers studies, the mean
SYNTAX score of 11.7 was lower than the 13.5 and 14.6 seen
in the LEADERS and RESOLUTE studies, respectively7,11; similarly
CSS tertile values in our study were lower compared with the
Figure 3 Receiver operating characteristic (ROC) curves for SYNTAX score and Clinical SYNTAX score. Left: 5-year major adverse cardiac
events. Middle: 5-year all-cause mortality (death). Right: 5-year cardiac death. AUC, area-under-the-curve, CI, confidence interval, CSS, Clinical
SYNTAX score.
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Table 4 Five-year all-cause mortality reclassification
into CSS tertiles
CSS tertiles
CSSLOW CSSMID CSSHIGH Total
Patients with events
SS tertiles SSLOW 14 1 3 18
SSMID 2 11 10 23
SSHIGH 0 1 30 31
Total 16 13 43 72
Patients without events
SS tertiles SSLOW 227 40 8 275
SSMID 39 174 51 264
SSHIGH 0 56 181 237
Total 266 270 240 776
SS, Clinical SYNTAX score; SS, SYNTAX score.
Score tertiles as defined in text.
Patients indicated in bold were moved to higher risk (above the diagonal) and
lower risk (below the diagonal) categories respectively, when reclassified.
SYNTAX score and Clinical SYNTAX score in the SIRTAX trial population 3121
RESOLUTE (0–11.2, .11.2–24.7, .24.7). This observation is not
surprising considering the differing time periods when patients
were enrolled in the three studies (SIRTAX 2003–2004,
LEADERS 2006–2007, RESOLUTE 2008), and the increasing
number of co-morbidities now seen in patients presenting for
revascularization. On the other hand, the ARTS II trial enrolled
patients during a similar time to the SIRTAX study; however,
inclusion criteria required patients to have at least two-vessel cor-
onary artery disease.25 The prevalence of multi-vessel disease in
SIRTAX was close to 60%,19 and therefore the lower mean and
tertile cut-off values, seen for the SYNTAX score and CSS in
the current study are entirely expected.
As mean SYNTAX score values decrease in patient cohorts with
less complex disease compared with the seminal SYNTAX trial,
one would hypothesize that differences in clinical outcomes
between individuals would go increasingly undetected by a score
solely based on angiographic parameters; clinical variables may
therefore compensate for this possible decrease in sensitivity of
the SYNTAX score. This hypothesis has been explored in
diverse patient populations by integrating clinical information
together with angiographic parameters into hybrid risk scores,
such as the CSS,11,18 the Global risk classification (GRC)10,26 and
the New Risk Stratification (NERS).27 In our study, we chose
CSS as the most parsimonious of these hybrid scores to assess
the incremental value of clinical data in risk stratification over
stand-alone SYNTAX score; thereby we tried to limit statistical
over-fitting and multiple collinearity between potential
predictors.28
The discriminatory power for MACE was similar for SYNTAX
score and CSS in our study; C-statistics were comparable with
the findings for 5-year MACE in the ARTS II (AUC: 0.57 and
0.62)18 and for 1-year MACE in the RESOLUTE (AUC: 0.59 and
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Table 5 Independent predictors of adverse events at 5-year follow-up (models including SYNTAX score)
Variables HR (95% CI)a P-value AUC (95% CI)c H–L x2 (P-value)c
MACE
SYNTAX scoreb 1.03 (1.01–1.05) 0.003 0.63 (0.58–0.68) 7.78 (0.46)
Number of lesions treated 1.54 (1.21–1.96) ,0.001
All-cause mortality
Ageb 1.06 (1.04–1.09) ,0.001 0.71 (0.65–0.78) 10.967 (0.20)
Diabetes mellitus 2.14 (1.32–3.46) 0.002
Cardiac death
Ageb 1.07 (1.03–1.11) ,0.001 0.75 (0.67–0.83) 5.425 (0.71)
Diabetes mellitus 2.01 (1.05–3.85) 0.04
LVEFb 0.97 (0.94–0.99) 0.006
AUC, area under the curve; CI, confidence interval; H–L, Hosmer–Lemeshow; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events.
aAfter adjustment for confounding factors.
bPer unit increase.
cFor the entire model.
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Table 6 Independent predictors of adverse events at 5-year follow-up (models including CSS)
Variables HR (95% CI)a P-value AUC (95% CI)c H–L x2 (P-value)c
MACE
CSSb 1.009 (1.005–1.013) ,0.001 0.65 (0.60–0.69) 10.214 (0.25)
Number of lesions treated 1.58 (1.24–2.01) ,0.001
All-cause mortality
CSSb 1.011 (1.006–1.015) ,0.001 0.68 (0.61–0.75) 7.576 (0.48)
Diabetes mellitus 2.21 (1.34–3.66) 0.002
Cardiac death
CSSb 1.012 (1.006–1.018) ,0.001 0.74 (0.65–0.82) 5.614 (0.69)
Diabetes mellitus 2.23 (1.13–4.39) 0.02
AUC, area under the curve; CI, confidence interval; CSS, Clinical SYNTAX score; H–L, Hosmer–Lemeshow; HR, hazard ratio; MACE, major adverse cardiac events.
aAfter adjustment for confounding factors.
bPer unit increase.
cFor the entire model.
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0.62)11 and better compared with the CUSTOMIZE registry left
main PCI population (AUC for 2-year MACE 0.52 and 0.50 for
SYNTAX score and CSS, respectively).10 Nevertheless, risk strati-
fication was not very well balanced between score tertiles; specifi-
cally, CSS showed diminished ability to discriminate between
patients at low and intermediate risk, reflecting findings of earlier
studies.10,18 SYNTAX score was recently shown to have higher dis-
criminatory power for repeat revascularization11; since MACE
rates were mainly driven by TLR rates in our study, the lack in
reclassification improvement with CSS can be explained.
On the other hand, for harder endpoints, such as the all-cause
and cardiac mortality, significantly better discrimination and equi-
valent or better calibration compared with SYNTAX score
translated into more refined risk stratification with the CSS.
Interestingly, whereas C-statistics for both scores regarding mor-
tality were comparable with respective measures in the ARTS II
and CUSTOMIZE populations, calibration measures were
improved in our study. This refinement in stratification resulted
in CSS being an independent predictor for mortality, contrary
to SYNTAX score, as also demonstrated in similar studies.11,13
Very long-term mortality is expected to be dependent on well-
known predictors of outcome after PCI, such as age and diabetes
mellitus; age is included in the CSS, while diabetes mellitus is
known to impact on renal function. Similarly, the EuroSCORE,29,30
which has also been shown to be effective in risk stratifying
patients, either as a stand-alone score or integrated in
GRC,10,26 does not include assessment of diabetic status, but
renal function. Diabetes was an independent predictor for all-
cause and cardiac mortality next to CSS in our study; nevertheless
a model incorporating CSS and diabetes did not significantly
improve discrimination or calibration for these outcomes. We
may assume that to a certain extent the effect of diabetes has
translated into higher angiographic complexity and diminished
creatinine clearance.
An added finding of our study is the differential performance of
PES and SES for patients in the highest SYNTAX score and CSS
tertiles. In the original SIRTAX trial publication,19 there was a sig-
nificant increase in the primary endpoint at 9-month follow-up in
patients allocated to PES compared with SES; this difference in
MACE was mainly driven by the increased TLR rates in the PES
treatment arm and was attributed to increased angiographic or
procedural complexity. In successive reports from the same
group, similarly significant differences in 2-year MACE have been
reported between PES and SES, when implanted in vessels with
a reference size ,2.75 mm,31 or when studied separately in dia-
betic patients.32 In both analyses, differences in MACE were
driven by significantly decreased TLR rates with SES. Not unex-
pectedly, in our study, significantly increased MACE rates with
PES were observed within the subgroup of patients with increased
angiographic complexity. It has already been suggested in the
LEADERS33 and the RESOLUTE11 trials, that SYNTAX score
could identify a subgroup of patients, where there is a difference
in clinical outcomes between devices. Nevertheless, in our study
respective hazard ratios were inflated, when MACE was stratified
across the CSS tertiles; more importantly, the respective inter-
action term between treatment arm and CSS tertiles reached stat-
istical significance for 5-year MACE, indicating a potential role of
CSS-based stratification in device selection. However, it should
be recognized that this was a subgroup analysis, not pre-specified
in the original study, thus the superiority seen with SES could be
the result of a type I error.
Limitations
The current study is limited by its post hoc nature. As the cardiol-
ogists adjudicating the diagnostic angiograms were blinded to pro-
cedural data, and taking into account the modest reproducibility of
SYNTAX score even among experienced cardiologists,34 a discre-
pancy in results cannot be ruled out, would the scores have been
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Table 7 Clinical outcomes at 1- and 5-year follow-up by treatment arm (univariable analysis)
PES, n 5 422, % SES, n5 426, % HR (95% CI) PES vs. SES P-value
1-year outcome
Death 2.1 1.4 1.53 (0.54–4.29) 0.42
Cardiac death 1.4 0.9 1.52 (0.43–5.40) 0.51
Myocardial infarction 4.1 2.8 1.44 (0.69–3.02) 0.33
TLR (ID) 10.8 5.7 1.95 (1.19–3.20) 0.008
MACE 13.6 7.5 1.86 (1.20–2.86) 0.005
Stent thrombosis (definite) 1.7 1.9 0.88 (0.32–2.44) 0.81
5-year outcome
Death 8.4 8.8 0.97 (0.61–1.54) 0.89
Cardiac death 5.1 4.6 1.13 (0.61–2.10) 0.70
Myocardial infarction 7.3 5.8 1.28 (0.75–2.20) 0.36
TLR (ID) 14.8 12.3 1.26 (0.87–1.82) 0.23
MACE 20.7 17.7 1.22 (0.90–1.67) 0.20
Stent thrombosis (definite) 4.2 4.1 1.02 (0.52–2.00) 0.96
CI, confidence interval; HR, hazard ratio; ID, ischaemia driven; MACE, major adverse cardiac events; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; TLR, target lesion
revascularization.
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Figure 4 Stratified comparison between treatment arms for clinical outcomes at 1-year follow-up. Events are stratified across Clinical
SYNTAX score tertiles defined as CSSLOW ≤8.0, 8.0 ,CSSMID ≤17.0, CSSHIGH .17.0. Clinical outcomes’ abbreviations as defined in text.
PES, paclitaxel-eluting stents, SES, sirolimus-eluting stents, N/A, non-applicable.
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Figure 5 Stratified comparison between treatment arms for clinical outcomes at 5-year follow-up. Events are stratified across Clinical
SYNTAX score tertiles defined as CSSLOW, 8.0, 8.0 , CSSMID ≤ 17.0, CSSHIGH . 17.0. Clinical outcomes’ abbreviations as defined in
text. PES, paclitaxel-eluting stents, SES, sirolimus-eluting stents.
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collected prospectively. However, in the case of the SIRTAX trial,
this is purely hypothetical, as the SYNTAX score algorithm had not
been developed at the time of patient enrolment.
Well-known limitations of the SYNTAX score should also be
acknowledged. Patients with prior CABG had to be excluded
from the study; moreover, scoring acute coronary occlusions as
total occlusions may have resulted in an inflation of the individual
scores overestimating the complexity of recanalization. However,
it has been recently shown that SYNTAX score values derived
after the instrumentation of the infarct-related artery and there-
fore probably lower compared with the values derived with the
standard method, could have resulted in an erroneous risk stratifi-
cation; it should not be overlooked that the absence of flow itself
holds an adverse impact on long-term outcome.9 Moreover, irre-
spective of the method used, SYNTAX score for acute MI patients
was proven to improve the discriminatory power of models solely
based on clinical variables, such as the TIMI risk score.35 Lastly, in
our study, multivariable analysis adjusted for clinical presentation,
rendering SYNTAX score and CSS as independent predictors of
MACE and CSS as independent predictor of mortality.
Conclusions
The SYNTAX score and to a greater extent the CSS were able to
stratify risk for very long-term adverse clinical outcomes in an
all-comers population receiving drug-eluting stents. Predictive
accuracy for 5-year mortality was improved using the CSS.
Within the highest score tertiles 5-year MACE increased with
use of paclitaxel- compared with sirolimus-eluting stents. This
study is yet another step to map the performance of SYNTAX
score and CSS in the entire range of coronary artery disease
seen in daily clinical practice.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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